perioperative chemotherapy-European Institute of Oncology-breast cancer

This refers to an investigational perioperative chemotherapy protocol developed by the **European Institute of Oncology (IEO)** for the treatment of endocrine non-responsive locally advanced breast cancer. The regimen specifically evaluates the efficacy of continuous intravenous infusion of **5-fluorouracil (5-FU)** during the surgical window and for two weeks post-operatively. 5-FU is a pyrimidine analog antimetabolite that inhibits thymidylate synthase, thereby disrupting DNA synthesis. In clinical trials, this perioperative 5-FU infusion was combined with preoperative chemotherapy regimens such as **ViFuP** (vinorelbine, cisplatin, and 5-FU) or **ECF** (epirubicin, cisplatin, and 5-FU). The protocol aims to target micrometastatic disease and reduce the risk of recurrence by maintaining cytotoxic levels of chemotherapy during and immediately following definitive surgery.

Other names

perioperative 5-fluorouracilperioperative5-fluorouracilperioperative-5-fluorouracilperioperative continuous infusion 5-FUPerioperative 5-FU in Operable Breast CancerPerioperative5-FU in Operable Breast CancerPerioperative-5-FU in Operable Breast Cancer